Introduction
============

Endoscopic retrograde cholangiopancreatography (ERCP) is the primary therapeutic procedure for treatment of diseases that affect the biliary tree and pancreatic duct. While the therapeutic success rate of ERCP is high, the procedure can cause complications, such as acute pancreatitis (PEP), bleeding, and perforation [@JR1290-1] .

PEP is the most common complication after ERCP. Previous studies estimate that their overall incidence after examination may range from 1 % to 10 % reaching an alarming 30 % in cases of patients at high risk [@JR1290-2] [@JR1290-3] . Stratification of degree of post-examination pancreatitis, based on previous statistics, demonstrates incidence rates of 3.6 % to 4 % for mild acute pancreatitis, 1.8 % to 2.8 % for moderate acute pancreatitis, and 0.3 % to 0.5 % for severe acute pancreatitis [@JR1290-4] [@JR1290-5] .

Risk factors for PEP include sex (female), age (30 to 40 years), and history of dysfunction in the sphincter of Oddi, pancreatitis, and biliary tree obstruction [@JR1290-1] [@JR1290-2] [@JR1290-6] . PEP may increase hospitalization time, drug use, rate of intensive care unit (ICU) admission, and incidence of pancreatic necrosis and edema, pseudocyst formation, inflammation or sepsis, and death (1 -- 3 % of patients) [@JR1290-7] . Therefore, prevention of PEP is critical to increasing patient safety and reducing healthcare burden.

Numerous studies have examined preventative measures for PEP, such as use of nonsteroidal anti-inflammatory drugs (NSAIDs) and placement of pancreatic stents. NSAIDs inhibit activation of intrapancreatic proteases, thereby preventing inflammatory cascade and reducing pancreatic lesions [@JR1290-8] [@JR1290-9] , whereas placement of a pancreatic stent is expected to maintain fluid secretion, which reduces papillary edema [@JR1290-10] .

Over the years, numerous families of drugs have been used as prophylactic medications, ranging from protease inhibitors (Pis) to antibiotics, hormonal drugs, antioxidants, heparin and anti-inflammatory cytokines. Drugs used for prevention of acute PEP, including corticosteroids, have been tested [@JR1290-11] .

Moreover, the PI aprotinin (Trasylol) was one of the first agents assayed for PEP [@JR1290-12] , and the drug was widely used for PEP in the 1970s and 1980s.

In recent systematic reviews, it is worth noting that recommendations emphasized use of topical epinephrine for the sphincter of Oddi and sublingual nitroglycerin in addition to parallel prescriptions for aggressive use of intravenous fluids [@JR1290-11] .

Use of indomethacin, aspirin, and other NSAIDs for treatment of acute pancreatitis has been investigated since the 1980 s [@JR1290-13] . Remarkably, indomethacin can induce PEP, although less frequently than cortisone [@JR1290-14] .

Considering the anti-inflammatory properties of NSAIDs for papillary edema and PEP, along with controversies about prevention of PEP with use of pharmacologic interventions, we conducted a systematic review and meta-analysis.

The current study aimed to compare efficacy of NSAIDs versus placebo in prevention of acute PEP after ERCP.

Materials and methods
=====================

Protocol and registry
---------------------

This systematic review and meta-analysis was performed in accordance with recommendations in the Cochrane Handbook, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [@JR1290-15] . The review was registered in PROSPERO international database under the number 42016049582.

Eligibility criteria and search procedure
-----------------------------------------

Only randomized controlled trials (RCTs) that assessed use of NSAIDs in preventing PEP were included. There was no restriction with regard to language and date of publication. Studies including use of pancreatic stents were excluded. Patients older than 18 years who underwent their first ERCP were included. Studies with alternative groups of patients were excluded from the analysis. NSAIDs and placebo were administered in the RCTs.

The primary ouctome of the studies selected was incidence of PEP. Secondary outcomes were severity of pancreatitis (mild, moderate, and severe), route of administration (rectal, intramuscular \[IM\], intravenous \[IV\], and oral), and types of NSAIDs (indomethacin, diclofenac, and others).

We thoroughly searched databases, such as MEDLINE, Embase, and Cochrane Central Library, from the start of the study until October 1, 2017.

The keywords used in searching MEDLINE were as follows: (Retrograde Cholangiopancreatography, Endoscopic OR Cholangiopancreatographies, Endoscopic Retrograde OR Endoscopic Retrograde Cholangiopancreatographies OR Retrograde Cholangiopancreatographies, Endoscopic OR Endoscopic Retrograde Cholangiopancreatography OR ERCP) AND (Pancreatitis) AND (AINES OR Diclofenaco OR Indomethacin OR Naproxen). For other databases, we combined simpler terms, such as ERCP AND Pancreatitis AND NSAID.

Evaluation of eligibility criteria and selection of studies were performed independently by two reviewers. Any disagreement was resolved by the authors after reaching a consensus. The selection process is outlined in the PRISMA flow chart [@JR1290-15] .

Each study was classified according to risk of bias, which considered clinical questions, randomization, allocation, blinding, loss to follow-up, prognostic factors, outcomes, and intention to treat analysis. We also used the JADAD scale (Jadad et al. 1996) [@JR1290-16] , which considers randomization, blinding of patients and investigators, and description of exclusion and losses.

Data analysis
-------------

Data were extracted based on intention to treat information. Absolute numbers, means and standard deviations were used for quantitative analysis. For every outcome and subgroup analysis, we calculated the RD with 95 % CI, and a *P*  \< 0.05 was considered significant. Analyses were carried out using RevMan 5.3 software. Due to the heterogeneity of studies, a statistical analysis using a random effect model was performed.

Results
=======

Twenty-one RCTs were considered eligible with a total of 6854 patients analyzed. Of the patients, 3427 used NSAIDs before ERCP (intervention) and 3427 did not use the drugs (control group) ( [Fig. 1](#FI1290-1){ref-type="fig"} ).

![ Selection of studies: PRISMA flowchart.](10-1055-a-0862-0215-i1290ei1){#FI1290-1}

With regard to route of administration, NSAIDs were administered via the rectum, IV, IM, and per OS in 12, three, one, and twp studies, respectively. The following NSAIDs were used: diclofenac [@JR1290-17] [@JR1290-18] [@JR1290-19] [@JR1290-20] [@JR1290-21] [@JR1290-22] [@JR1290-23] [@JR1290-24] [@JR1290-25] [@JR1290-26] [@JR1290-27] [@JR1290-28] , indomethacin [@JR1290-11] [@JR1290-29] [@JR1290-30] [@JR1290-31] [@JR1290-32] [@JR1290-33] [@JR1290-34] , naproxen [@JR1290-35] , valdecoxib [@JR1290-8] , and ketoprofen [@JR1290-36] . Study characteristics are outlined in [Table 1](#TB1290-1){ref-type="table"} .

###### Study characteristics.

  Reference                             Year   Country    Administration             Single dose    Type of NSAID
  ------------------------------------- ------ ---------- -------------------------- -------------- ---------------
  Andrade et al. 2015 [@JR1290-28]      2015   México     Rectal                     100 mg         Indomethacin
  Bhatia et al. 2011 [@JR1290-5]        2011   India      Intravenous                20 mg          Valdecoxib
  Cheon et al. 2007 [@JR1290-25]        2007   USA        Oral                       50 mg          Diclofenac
  Döbrönte et al. 2014 [@JR1290-30]     2014   Hungary    Rectal                     100 mg         Indomethacin
  Elmunzer et al. 2012 [@JR1290-14]     2012   USA        Rectal                     100 mg         Indomethacin
  Hauser et al. *2016* [@JR1290-19]     2016   Croatia    Rectal                     100 mg         Diclofenac
  Ishiwatari et al. 2016 [@JR1290-17]   2016   Japan      Oral                       100 mg         Diclofenac
  Khoshbaten et al. 2008 [@JR1290-21]   2008   Irán       Rectal                     50 mg          Diclofenac
  Leerhoy et al. 2016 [@JR1290-18]      2016   Denmark    Rectal                     100 mg         Diclofenac
  Levenick et al. 2016 [@JR1290-29]     2016   USA        Rectal                     100 mg         Indomethacin
  Lua et al. 2015 [@JR1290-15]          2015   Malaysia   Rectal                     100 mg         Diclofenac
  Mansour et al. 2016 [@JR1290-32]      2016   Irán       Rectal                     500 mg         Naproxen
  Montaño et al. 2007 [@JR1290-27]      2007   México     Rectal                     100 mg         Indomethacin
  Mousalreza et al. 2016 [@JR1290-31]   2016   Irán       Rectal                     100 mg         Indomethacin
  Murray et al. 2003 [@JR1290-24]       2003   Scotland   Rectal                     100 mg         Diclofenac
  Otsuka et al. 2012 [@JR1290-23]       2012   Japan      Rectal                     50 mg          Diclofenac
  Park et al. 2014 [@JR1290-16]         2014   Korea      Intramuscular              100 mg         Diclofenac
  Patai et al. 2015 [@JR1290-26]        2015   Hungary    Rectal                     100 mg         Indomethacin
  Quadros et al. 2016 [@JR1290-33]      2016   Brazil     Intravenous                100 mg         Ketoprofen
  Senol et al. 2009 [@JR1290-20]        2009   USA        Intravenous                50 mg          Diclofenac
  Uçar et al. 2016 [@JR1290-22]         2016   Turkey     Intramuscular and rectal   75 -- 100 mg   Diclofenac

In assessment of risk of bias, all articles presented adequate randomization, allocation, and blinding. Losses occurred in five RCTs. However, the value did not reach 20 %. In all studies, the JADAD score was above 3, which is satisfactory for inclusion in this systematic review. The bias assessment summary is outlined in [Table 2](#TB1290-2){ref-type="table"} .

###### Descriptive table of the studies.

  Author                                Randomization   Allocation   Blinding   Losses   Prognosis     IIT   JADAD
  ------------------------------------- --------------- ------------ ---------- -------- ------------- ----- -------
  Andrade et al. 2015 [@JR1290-28]      Yes             Yes          No         No       Homogeneous   Yes   3
  Bhatia et al. 2011 [@JR1290-5]        Yes             Yes          No         No       Homogeneous   No    3
  Cheon et al. 2007 [@JR1290-25]        Yes             Yes          Yes        Yes      Homogeneous   No    5
  Döbrönte et al. 2014 [@JR1290-30]     Yes             No           No         Yes      Homogeneous   No    3
  Elmunzer et al. 2012 [@JR1290-14]     Yes             Yes          Yes        No       Homogeneous   Yes   5
  Hauser et al. 2016 [@JR1290-19]       Yes             Yes          Yes        No       Homogeneous   Yes   5
  Ishiwatari et al. 2016 [@JR1290-17]   Yes             Yes          Yes        Yes      Homogeneous   No    3
  Khoshbaten et al. 2008 [@JR1290-21]   Yes             Yes          Yes        No       Homogeneous   No    5
  Leerhoy et al. 2016 [@JR1290-18]      Yes             No           No         No       Homogeneous   No    3
  Levenick et al. 2016 [@JR1290-29]     Yes             Yes          Yes        No       Homogeneous   Yes   5
  Lua et al. 2015 [@JR1290-15]          Yes             Yes          No         Yes      Homogeneous   Yes   3
  Mansour et al. 2016 [@JR1290-32]      Yes             Yes          Yes        No       Homogeneous   Yes   4
  Montaño et al. 2007 [@JR1290-27]      Yes             No           Yes        No       Homogeneous   No    3
  Mousalreza et al. 2016 [@JR1290-31]   Yes             Yes          Yes        No       Homogeneous   No    3
  Murray et al. 2003 [@JR1290-24]       Yes             Yes          Yes        No       Homogeneous   No    3
  Otsuka et al. 2012 [@JR1290-23]       Yes             No           No         No       Homogeneous   Yes   3
  Park et al. 2014 [@JR1290-16]         Yes             Yes          Yes        No       Homogeneous   No    3
  Patai et al. 2015 [@JR1290-26]        Yes             Yes          Yes        Yes      Homogeneous   Yes   5
  Quadros et al. 2016 [@JR1290-33]      Yes             Yes          Yes        No       Homogeneous   Yes   5
  Senol et al. 2009 [@JR1290-20]        Yes             No           No         No       Homogeneous   No    3
  Uçar et al. 2016 [@JR1290-22]         Yes             No           No         No       Homogeneous   Yes   3

Time to diagnose in individuals with PEP varied among studies from 90 minutes to 72 hours post-ERCP, and patients met at least two of the three major diagnostic criteria: history of abdominal pain, increase in amylase level, and imaging study results consistent with PEP.

Incidence of post-ERCP pancreatitis
-----------------------------------

All 21 articles assessed incidence of PEP and compared 3427 patients in each group. In total, 250 events were observed in the NSAID group and 407 in the control group. The RD was −0.05 (95 % CI, --0.07 to --0.03; *P*  \< 0.05). The number needed to treat (NNT) was 20. Forest plots of the incidence of post-ERCP PEP are shown in [Fig. 2](#FI1290-2){ref-type="fig"} .

![ Forest plots on PEP incidence.](10-1055-a-0862-0215-i1290ei2){#FI1290-2}

Severity of pancreatitis
------------------------

### Mild pancreatitis

Patients presented with mild pancreatitis in 14 of the 21 studies. In total, 136 of 2600 patients and 203 of 2569 patients in the NSAID and control groups, respectively, presented with the condition. Incidence of mild pancreatitis in the intervention group decreased, with an RD of −0.03 (95 % CI, −0.05 to -- 0.01; *P*  \< 0.05). The NNT was 33.

### Moderate pancreatitis

Patients presented with moderate pancreatitis in 11 of 21 RTCs. In total, 54 of 2134 patients and 89 of 2150 patients in the NSAID and control groups, respectively, had the condition. The RD was −0.01 (95 % CI, −0.02 to 0.00; *P*  \> 0.05).

### Severe pancreatitis

Patients presented with severe pancreatitis in seven of 21 studies. In total, 16 of 1740 patients and 23 of 1747 patients in the NSAID and control groups, respectively, had the condition. No statistical difference was observed between the methods with RD −0.00 (95 % CI, −0.01 to 0.00; *P*  \> 0.05).

Forest plots summarizing the analyses of the severity of the pancreatitis are shown in [Fig. 3](#FI1290-3){ref-type="fig"} .

![ Forest plots assessing NSAID efficacy according to pancreatitis severity.](10-1055-a-0862-0215-i1290ei3){#FI1290-3}

Routes of administration
------------------------

With regard to routes of drug administration, rectal administration was the most commonly used route. In 15 studies, 4988 patients preferred rectal administration. In total, 170 of 2492 patients in the NSAID group and 324 of 2496 patients in the control group presented with PEP. The RD was −0.07 (95 % CI, −0.10 to --0.04; *P*  \< 0.05). The NTT was 20.

Six studies that used other administration routes (PO, IV, and IM) have reported that 80 of 935 patients and 83 of 931 patients in the NSAID and control groups, respectively, presented with PEP. The RD was −0.00 (95 % CI, −0.02 to 0.02; *P*  \> 0.05). Routes of administration and associated efficacies are summarized in [Fig. 4](#FI1290-4){ref-type="fig"} .

![Forest plots assessing PEP according to route of drug administration and NSAID type.](10-1055-a-0862-0215-i1290ei4){#FI1290-4}

Types of NSAIDs
---------------

In 11 studies, diclofenac was used, and PEP was observed in 121 of 1421 patients in the NSAID group and 184 of 1403 patients in the control group. The RD was −0.05 (95 % CI, −0.09 to -- 0.02; *P*  \< 0.05). The NTT was 20.

Seven RCTs evaluated efficacy of indomethacin in preventing PEP. In total, 100 of 1493 patients in the NSAID group and 178 of 1484 patients in the control group presented with PEP. The RD was --0.06 (95 % CI, −0.10 to −0.02; *P*  \< 0.05) and the NNT was 17.

In three studies, other NSAIDs (valdecoxib, naproxen, and ketoprofen) were used for prevention of PEP. In total, 29 of 513 patients and 45 of 542 patients in the NSAID and control groups, respectively, presented with PEP. The RD was −0.03 (95 % CI, −0.09 to 0.03; *P*  \> 0.05) and the NNT was 20.

[Fig. 5](#FI1290-5){ref-type="fig"} summarizes the meta-analysis on types of NSAIDs.

![ Forest plots assessing types of NSAIDs used to prevent PEP.](10-1055-a-0862-0215-i1290ei5){#FI1290-5}

Discussion
==========

The impact of periprocedural NSAIDs during ERCP has been extremely compelling within the last 4 to 5 years. Although the results were conflicting, major international societies have endorsed their routine prescription. The European Society of Comparative Gastroenterology recommends administering NSAIDs (diclofenac or indomethacin 100 mg) rectall before or after ERCP if no contraindications are observed [@JR1290-37] . Analogously, the American Society for Gastrointestinal Endoscopy [@JR1290-38] is in favor of administration of NSAIDs after contraindications have been ruled out. However, this is only applicable in high-risk individuals. Meanwhile, use of indomethacin for average-risk patients is also recommended.

As regards the Japanese Guidelines by the Japanese Ministry of Health, they advoacte a similar policy for intrarectal administration of NSAIDs in all cases of ERCP with no contraindications [@JR1290-39] . The current study is based on these foundations with consideration for several unclear details.

Unlike other systematic reviews on use of NSAIDs to reduce risk of developing PEP [@JR1290-3] [@JR1290-40] [@JR1290-41] , the current study included only RCTs in which a subgroup analysis was conducted of the efficacy of such medications according to the severity of PEP, administration route, and drug type. Pooled results of these 21 randomized studies showed a significant reduction in risk of developing PEP with use of NSAIDs. However, the effect was restricted to mild cases. Furthermore, these studies showed the efficacy of rectal administration of diclofenac and indomethacin.

Due to the scarce number of randomized studies published in the literature, it was not possible to identify whether other NSAID administration routes are effective in preventing PEP beyond the rectal route and we consider this a limitation of our study. Large RCTs and multicenter studies are needed comparing administration techniques for these NSAIDs as well as other different types of NSAIDs for evaluation and comparison of efficacy in preventing PEP post-ERCP.

Rectal administration of NSAIDs is the most commonly used method for preventing PEP. A standard recommended dose has not been established, although most studies used 100 mg daily. Rectal administration of diclofenac or indomethacin using this dose is highly effective for prevention of PEP. Physicians performing ERCP will decide what drug to use. However, their decisions may also be influenced by cost because indomethacin is more expensive than diclofenac. A cost comparison of NSAIDs for decreasing incidence of PEP must be conducted.

To the best of our knowledge, this is the first meta-analysis on prevention of PEP with use of NSAIDs, which include all types of such drugs (diclofenac, indomethacin, naproxen, valdecoxib, and ketoprofen). Both diclofenac and indomethacin are highly effective. The putative mechanism of action of these agents is inhibition of phospholipase A2, which leads to a decrease in the inflammatory cascade and downregulation of pro-inflammatory factors, such as leukotrienes, prostaglandins, and platelet-activating agents, and this mechanism reduced inflammatory lesions and organ necrosis [@JR1290-8] [@JR1290-9] . Thus, lack of efficacy of other agents may result in reduced target inhibition with the dose used or pharmacokinetics that are disadvantageous. Nonetheless, the efficacy of other NSAIDs must be further investigated.

It is important to emphasize that our results may have been influenced by confounders, such as the experience of endoscopists, the endoscopic devices used, technical level and extent of nursing care, sedation method, and the type and amount of contrast agent used in the biliary tract. Moreover, several demographic factors influence risk of developing PEP, including sex (female), younger age, and obesity. Thus, patient sex ratio, age, and body mass index may have influenced overall incidence in the individual RCTs. Furthermore, risk for PEP increased with presence of specific diseases (dysfunction of the sphincter of Oddi, choledocholithiasis, biliary tract, and pancreatic tumors). Future studies must include both intervention and control groups. In addition, diagnosis of PEP and its changes post-ERCP showed a substantial heterogeneity among the studies, which included time of evaluation after the procedure (from 90 minutes to 72 hours), clinical symptoms (pain, nausea, and vomiting), and use of imaging data (tomography) [@JR1290-11] [@JR1290-18] [@JR1290-19] [@JR1290-20] [@JR1290-21] [@JR1290-22] [@JR1290-23] [@JR1290-24] [@JR1290-25] [@JR1290-26] [@JR1290-27] [@JR1290-28] [@JR1290-29] [@JR1290-30] [@JR1290-31] [@JR1290-32] [@JR1290-33] [@JR1290-34] [@JR1290-35] [@JR1290-36] [@JR1290-41] .

Another limitation of our manuscript was that not all RCTs stratified the degree of pancreatitis, and when they did, it was not standardized and uniform. A total of 657 cases of PEP was reported (with and without use of NSAIDs). For 521 patients, the degree of pancreatitis involvement was specified. In 339 of thse cases, patients were defined as having mild intensity pancreatitis, which represents a total of 65 % of the stratified patients (339/521). Thus, our results demonstrated that NSAID use is superior for prevention inr patients who developed mild PEP post-ERCP.

Finally, the current systematic review focused only on incidence of PEP and its intensity. However, other complications that affect patient outcome after ERCP, such as perforations and bleeding, were not evaluated.

Nonetheless, this systematic review showed that rectal administration of diclofenac and indomethacin are effective in preventing acute PEP after ERCP. Compared to other methods used to prevent PEP, such as use of pancreatic stents [@JR1290-42] [@JR1290-43] , NSAIDs are more convenient to administer, and such drugs are less expensive. Reducing incidence of PEP not only increases patient safety but also reduces healthcare burden by decreasing the rate of hospitalization and ICU stay.

Conclusion
==========

Rectal administration of NSAIDs adequately reduces incidence of acute PEP after ERCP. Mild pancreatitis is the only preventable outcome. In this context, both diclofenac and indomethacin are considered effective. Further RCTs are needed to compare efficacy between NSAID administration pathways in prevention of acute pancreatitis after ERCP.
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